All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to BuyZacks Investment Research • 04/14/23
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model TransitionBusiness Wire • 04/07/23
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne PharmaBusiness Wire • 12/04/22
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive OfficersBusiness Wire • 09/12/22
TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022Business Wire • 08/08/22
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And MoreBenzinga • 06/21/22
TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder PushbackSeeking Alpha • 06/16/22